A University of Alberta research team has developed a more effective way to deliver topical pain relief for chronic conditions like arthritis.
Topical non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac have traditionally been compounded by pharmacists in creams or gels using five, 10 or an even higher percentage of the active ingredient.
The new product, FoamaDerm®, is a microemulsion foam that has been shown to provide pain relief at just two per cent strength.
The foam was developed at the University of Alberta's Drug Development and Innovation Center (DDIC) under the direction of Dr. Raimar Löbenberg, professor in the Faculty of Pharmacy and Pharmaceutical Sciences.

The team was asked by a major insurance company about the effectiveness of diclofenac compounds, in comparison to commercially available, lower-strength products such as Voltaren.
"In our studies, we showed that many of the dosage forms don't release the drug appropriately, so I asked my students, 'Can we make something better? Let's try putting the active ingredient in a microemulsion instead,'" Löbenberg says.
"We found that we doubled the release compared with other products on the market."
Doctors may prescribe topical pain relief medications instead of oral NSAIDs because there is less risk of severe stomach upset or ulcers.
Löbenberg and his colleagues formed a company, RS Therapeutics Inc., which now sells FoamaDerm as a base to pharmacies throughout Canada. They have also set up a laboratory in North Carolina and are working to make it available in the United States.
The new product is a clear liquid made of water and coconut oil that allows the active ingredient to penetrate the stratum corneum, or outer layer of the skin, which Löbenberg describes as "like a rubber coat." The propellant-free dispensing pump foams the product, making it easy to apply. When it is rubbed in, the foam disappears, leaving no residue on the skin or clothing.